Evidence map›Paper›PMID 32238878›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2020

Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1.

Andrés E Quesada, Guillermo Montalban-Bravo, Rajyalakshmi Luthra, Keyur P Patel, Koji Sasaki, Carlos E Bueso-Ramos, Joseph D Khoury, Mark J Routbort, Roland Bassett, Juliana E Hidalgo-Lopez and 9 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. The Growing Role of the BH3 Mimetic Drug Venetoclax in the Therapy of Acute Myeloid Leukemia.Mediterranean journal of hematology and infectious diseases · 2022
    Review
  10. Review
  11. Incidental identification of inv(16)(p13.1q22)/Cold Spring Harbor molecular case studies · 2021
    Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Andrés E Quesada *Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Guillermo Montalban-Bravo *Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Rajyalakshmi LuthraDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Keyur P PatelDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Koji SasakiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Carlos E Bueso-RamosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Joseph D KhouryDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.ORCID http://orcid.org/0000-0003-2621-3584
Mark J RoutbortDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.ORCID http://orcid.org/0000-0003-4860-261X
Roland BassettDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA.
Juliana E Hidalgo-LopezDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Chong ZhaoDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Pei LinDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Sanam LoghaviDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.ORCID http://orcid.org/0000-0001-8980-3202
Chi Y OkDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.ORCID http://orcid.org/0000-0002-6822-7880
Tapan KadiaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Courtney D DiNardoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.ORCID http://orcid.org/0000-0001-9003-0390
Hagop KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Rashmi Kanagal-ShamannaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA. RKanagal@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
6 · The paper itself

Abstract

We studied the characteristics of the provisional category de novo acute myeloid leukemia (AML) with mutated RUNX1 (AML-RUNX1

Indexed as

AgedCell LineCore Binding Factor Alpha 2 SubunitFemaleHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMutationNucleophosminPrognosisWorld Health OrganizationCore Binding Factor Alpha 2 SubunitNPM1 protein, humanNucleophosmin

Identifiers

PMID32238878
OpenAlexW3014522914

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.